Srinivas Akkaraju decided not to stand for re-election as a director after completing his term at aTyr Pharma Inc.'s 2018 annual meeting of stockholders on May 15.

Akkaraju's decision not to stand for re-election was not a result of a disagreement with management regarding the company's operations, policies, practices or otherwise, according to ATyr Pharma.

San Diego, Calif.-based aTyr Pharma is a clinical stage biotherapeutics company, which engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases.